Improving the pharmacokinetics, biodistribution and plasma stability of monobodies
Cancer is a leading cause of death worldwide. Several targeted anticancer drugs entered clinical practice and improved survival of cancer patients with selected tumor types, but therapy resistance and metastatic disease remains a challenge. A major class of targeted anticancer drugs are therapeutic...
Main Authors: | Adrian Valentin Dinh-Fricke, Oliver Hantschel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1393112/full |
Similar Items
-
Monobodies and nanobodies: The era of diagnostic miniature antibodies
by: Ruby Dhar, et al.
Published: (2023-10-01) -
Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain
by: Peter G. Chandler, et al.
Published: (2020-03-01) -
Monobodies as possible next-generation protein therapeutics – a perspective
by: Oliver Hantschel
Published: (2017-11-01) -
Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains
by: Martin Siegemund, et al.
Published: (2021-10-01) -
Plasma Protein Binding Rate and Pharmacokinetics of Lekethromycin in Rats
by: Pan Sun, et al.
Published: (2022-09-01)